Gurnet Point Capital and Patient Square Capital completed the acquisition of Radius Health for $890 million. Radius shareholders received $10 per share. Also, if abaloparatide reaches $300 million in TTM sales by December 31, 2025, shareholders will receive another $1 per share.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept